Inogen (INGN) Cash & Equivalents (2012 - 2026)

Inogen (INGN) has 15 years of Cash & Equivalents data on file, last reported at $93.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $93.1 million, down 21.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.1 million (down 21.68% YoY), and the FY2025 annual result was $103.7 million, down 11.66% from the prior year.
• Cash & Equivalents retreated to $93.1 million in Q1 2026 per INGN's latest filing, from $103.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $223.6 million in Q2 2022 and troughed at $23.7 million in Q3 2023.
• A 5-year average of $125.2 million and a median of $107.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 88.82% in 2023, then soared 350.23% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $187.0 million in 2022, then tumbled by 32.9% to $125.5 million in 2023, then dropped by 6.44% to $117.4 million in 2024, then fell by 11.66% to $103.7 million in 2025, then retreated by 10.24% to $93.1 million in 2026.
• Business Quant data shows INGN's Cash & Equivalents at $93.1 million in Q1 2026, $103.7 million in Q4 2025, and $106.5 million in Q3 2025.